Abstracts tagged "anti-TNF therapy"

Abstract Number: 557 • 2018 ACR/ARHP Annual Meeting
The Impact of Comedication with Conventional Synthetic Dmards on Drug Retention and Clinical Effectiveness of Tofacitinib, Anti–Tumor Necrosis Factor Therapy and Biologics with an Alternative Mode of Action in Patients with Rheumatoid Arthritis. a Cohort Study
Axel Finckh¹, Christophe Tellenbach², Almut Scherer², Burkhard Moeller³, Adrian Ciurea⁴, Ines von Mühlenen⁵, Cem Gabay⁶, Diego Kyburz⁷, Ruediger Mueller⁸, Paul Hasler⁹ and Pascal Zufferey¹⁰, ¹University Hospital of Geneva, Geneva, Switzerland, ²SCQM Foundation, Zurich, Switzerland, ³Rheumatology, Immunology and Allergology, Inselspital, University Hospital of Bern, Bern, Switzerland, ⁴Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁵Rheuma-Basel, Basel, Switzerland, ⁶University Hospitals of Geneva, Geneva, Switzerland, ⁷Rheumatology, University Hospital Basel, Basel, Switzerland, ⁸Division of Rheumatology, Kantonsspital St Gallen, St. Gallen, Switzerland, ⁹Kantonsspital Aarau AG, Aarau, Switzerland, ¹⁰Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland
Background/Purpose: Co-medication with conventional synthetic DMARDs (csDMARDs) is currently recommended with all targeted therapies (bDMARDs and tsDMARDs) for the management of rheumatoid arthritis (RA). However,…
Abstract Number: 2558 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety Outcomes in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol: Results from the 48-Week Run-in Part of a Withdrawal Study (NCT02505542)
Robert B.M. Landewé¹, Désirée van der Heijde², Maxime Dougados³, Xenofon Baraliakos⁴, Filip van Den Bosch⁵, Bengt Hoepken⁶, Karen Thomas⁶ and Lianne S. Gensler⁷, ¹Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam and Zuyderland MC, Heerlen, Netherlands, ²Leiden University Medical Centre, Leiden, Netherlands, ³Rheumatology B Department, Paris-Descartes University and Cochin Hospital, Paris, France, ⁴Ruhr-University Bochum, Herne, Germany, ⁵Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium, ⁶UCB Pharma, Monheim, Germany, ⁷University of California, San Francisco, CA
Background/Purpose: C-OPTIMISE is the first trial to evaluate whether certolizumab pegol (CZP) can be reduced/discontinued in patients with radiographic(r)-axSpA/ankylosing spondylitis (AS) and non-radiographic(nr)-axSpA achieving sustained…
Abstract Number: 559 • 2018 ACR/ARHP Annual Meeting
Radiographic Progression Based on Baseline Demographics and Disease Characteristics from Three TNF-Alpha Inhibitor Biosimilar Studies in Patients with Rheumatoid Arthritis
Josef S. Smolen¹, Young Mo Kang², Wan-Hee Yoo³, Paul Emery⁴, Michael E Weinblatt⁵, Edward C. Keystone⁶, Mark C. Genovese⁷, Gihyun Myung⁸, Evelyn Hong⁸, Inyoung Baek⁸ and Jeehoon Ghil⁸, ¹Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²Kyungpook National University School of Medicine, Daegu, Korea, Republic of (South), ³Chonbuk National University School of Medicine, Jeonju, Korea, Republic of (South), ⁴University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Mount Sinai Hospital, Toronto, ON, Canada, ⁷Stanford University Medical Center, Palo Alto, CA, ⁸Samsung Bioepis Co., Ltd., Incheon, Korea, Republic of (South)
Background/Purpose: SB4, SB2, and SB5 are biosimilars of reference etanercept, infliximab, and adalimumab, respectively. Radiographic data were assessed using the modified Total Sharp Score (mTSS)…
Abstract Number: 2580 • 2018 ACR/ARHP Annual Meeting
Predicting Treatment Persistence and Non-Persistence of Newly Initiated TNF Inhibitor Therapy in Ankylosing Spondylitis Patients: A Gender Comparison
Theresa Hunter¹, Atul A. Deodhar², Rebecca Bolce¹, Krista Schroeder¹ and David Sandoval Calderon¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Oregon Health & Science U, Portland, OR
Background/Purpose: The purpose of this study was to compare treatment patterns in the 2 years following the initiation of TNF inhibitor (TNFi) in AS patients.Methods:…
Abstract Number: 638 • 2017 ACR/ARHP Annual Meeting
Are There Clinical Demographic or Subclinical Ultrasonographic Data That Can Predict Flare in Psoriatic Arthritis Patients during a Phase of Minimal Disease Activity after Spacing of Anti-TNF Blockers Injections?
Pierluigi Macchioni¹, Giovanni Ciancio², Gilda Sandri³, Alen Zabotti⁴, Luca Montaguti⁵, Gentiana Vukatana⁶, Fabio Mascella⁷, Donatella Chessa⁸, Elisa Verduci⁹, Marcello Govoni¹⁰, Amelia Spinella³, Francesca Zuliani¹¹, Marco Bruschi⁵, Nazzarena Malavolta¹² and Mariacristina Focherini⁷, ¹Rheumatology Unit, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ²Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliera-Universitaria Sant’Anna - Ferrara (Italy), ferrara, Italy, ³Rheumatology Unit, University fo Modena & Reggio, Modena, Italy, ⁴Rheumatology Clinic, Department of Medical and Biological Sciences, Santa Maria della Misericordia" University Hospital, Udine, Italy, ⁵Dipartimento Internistico SS di Reumatologia, AUSL Romagna Ospedale Bufalini, Cesena, Italy, ⁶Rheumatology Unit, Department CardioThoracic Vascular, S.Orsola- Malpighi Hospital, Alma Mater Studiorum, Bologna, Bologna, Italy, ⁷Internal Medicine and Rheumatology, Ospedale Infermi Rimini, Rimini, Italy, ⁸Internal Medicine, Ospedale Paolo Dettori, Tempio Pausania, Italy, ⁹Rheumatology Unit, Arcispedale S. Maria Nuova, Reggio Emilia, Italy, ¹⁰Rheumatology Clinic, Department of Medical and Biological Sciences, University of Ferrara and Azienda Ospedaliera-Universitaria Sant’Anna - Ferrara (Italy), ferrara, Italy, ¹¹Rheumatology Unit, Department of Medical Sciences, Santa Maria della Misericordia" University Hospital, Udine, Italy, ¹²Policlinico S.Orsola-Malpighi, Azienda Ospedaliero-Universitaria of Bologna, Bologna, Italy
Background/Purpose: Tumour necrosis factor (TNF)-blocker tapering has been proposed for patients with psoriatic arthritis (PA) in clinical remission. To evaluate if there are clinical, demographic…
Abstract Number: 1825 • 2017 ACR/ARHP Annual Meeting
Comparative Analysis of Achievement of Individual Important Response Measured By DAS28dcrit in a Randomized Head-to-Head Trial of Tocilizumab Vs. Adalimumab in Active Rheumatoid Arthritis
Michaela Koehm¹, Michael Hofmann², Rasmus Lüthje², Matthew McIntosh³, Varghese Abraham³, Cem Gabay⁴, Arthur Kavanaugh⁵, Harald Burkhardt⁶ and Frank Behrens⁶, ¹Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt/Main, Germany, ²Rheumatology, Chugai Pharma Europe Ltd., Frankfurt, Germany, ³Genentech, San Francisco, CA, ⁴SCQM, Geneva, Switzerland, Geneva, Switzerland, ⁵Medicine, University of California, San Diego, La Jolla, CA, ⁶Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany
Background/Purpose: Fluctuations in disease activity due to short-term situational effects and measurement errors are important considerations for evaluation of individual clinically meaningful therapeutic response in…
Abstract Number: 1019 • 2017 ACR/ARHP Annual Meeting
Molecular Profiling of RA Patients Suggests a Differential Involvement of Adaptive and Innate Cell Populations in Response to Anti-TNF Treatment
Victor Farutin¹, Thomas Prod'homme¹, Kevin McConnell¹, Nathaniel Washburn¹, Patrick Halvey¹, Jamey Guess¹, Nur Sibel Gunay¹, Jan Hillson², Carol J. Etzel³, Katherine C. Saunders³, Dimitrios A. Pappas^3,4, Anthony Manning¹, Leona Ling¹ and Ishan Capila¹, ¹Research, Momenta Pharmaceuticals, Inc., Cambridge, MA, ²Clinical Research, Momenta Pharmaceuticals, Inc., Cambridge, MA, ³Corrona, LLC, Southborough, MA, ⁴Columbia University, New York, NY
Background/Purpose: Despite the success of anti-TNF therapies in RA, ~ 30 % of patients are non-responders. Several studies have focused on understanding the biology underlying…
Abstract Number: 1905 • 2017 ACR/ARHP Annual Meeting
Sustained Response Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial
Joel Kremer¹, William F C Rigby², Nora Singer³, Christine Birchwood⁴, Darcy Gill⁴, William Reiss⁴, Jinglan Pei⁴ and Margaret Michalska⁴, ¹Albany Medical College, Albany, NY, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Case Western Reserve University School of Medicine, Cleveland, OH, ⁴Genentech, Inc., South San Francisco, CA
Background/Purpose: Although methotrexate (MTX) is often administered in combination with biologics for the treatment of rheumatoid arthritis (RA), it may be discontinued due to intolerance…
Abstract Number: 1049 • 2017 ACR/ARHP Annual Meeting
Heart Rate Variability Testing with Autonomic Nervous System Optimization: Could It Change the Course of Spending for Rheumatoid Arthritis Patients in the U.S.? an Exploratory Minimal Model Analysis
Marita Zimmermann¹, Elisabeth Vodicka², Andrew J Holman^3,4,5 and Louis P Garrison², ¹Constants in Global Health, University of Washington, Seattle, WA, ²Consultants in Global Health, University of Washington, Seattle, WA, ³Rheumatology, Pacific Rheumatology Associates Inc PS, Seattle, WA, ⁴Inmedix, Normandy Park, WA, ⁵Pacific Rheumatology Reseach, Seattle, WA
Background/Purpose: Autonomic nervous system (ANS) testing with heart rate variability (HRV) has been shown to predict 52-week anti-TNF therapeutic outcomes in rheumatoid arthritis (RA).1 HRV…
Abstract Number: 2449 • 2017 ACR/ARHP Annual Meeting
Comparative Effectiveness of Tocilizumab (TCZ) Monotherapy with Tumor Necrosis Factor Inhibitors (TNFi) in Combination with Varying Doses of Methotrexate (MTX) in Patients with Rheumatoid Arthritis
Leslie R Harrold¹, George W. Reed¹, Jennie Best², Steve Zlotnick², Gioia Persuitte³ and Joel Kremer⁴, ¹University of Massachusetts Medical School, Worcester, MA, ²Genentech, Inc., South San Francisco, CA, ³Corrona, LLC, Southborough, MA, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Clinical studies have shown that the efficacy of TCZ monotherapy (TCZ mono) is superior to that of TNFi monotherapy and comparable to that of…
Abstract Number: 1057 • 2017 ACR/ARHP Annual Meeting
Budgetary Impact Analysis of Real-World Dosing Patterns in Matched Cohorts of Rheumatoid Arthritis Patients Treated with Infliximab or Golimumab Intravenous Anti-TNF Medications
Lorie A. Ellis¹, Elisabetta Malangone-Monaco², Helen Varker², Diana Stetsovsky³, Maureen Kubacki⁴, Raphael J. DeHoratius⁵ and Shelly Kafka⁴, ¹Janssen HECOR Immunology, Horsham, PA, ²Truven Health Analytics, Bethesda, MD, ³Truven Health Analytics, Philadelphia, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Janssen Scientific Affairs, LLC/Sidney Kimmel School of Medicine, Thomas Jefferson University, Horsham/Philadelphia, PA
Background/Purpose: Infliximab (IFX) is more frequently selected than golimumab for intravenous use (GLM-IV) in patients with Rheumatoid Arthritis (RA) but differences in dosing and administration…
Abstract Number: 2451 • 2017 ACR/ARHP Annual Meeting
Rapid Onset of Response Observed with Certolizumab Pegol in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Efficacy and Safety Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study
Liqi Bi¹, Yuhui Li², Lan He³, Huji Xu⁴, Jieruo Gu⁵, Guochun Wang⁶, Zhiyi Zhang⁷, Yi Liu⁸, Marion Boehnlein⁹, Jochen Dunkel⁹, Jing Shao¹⁰, Kristina Harris¹¹ and Zhanguo Li¹², ¹China-Japan Union Hospital of Jilin University*, Changchun, China, ²Peking University People’s Hospital*, Beijing, China, ³The First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China, ⁴Shanghai Changzheng Hospital, Shanghai, China, ⁵Sun Yat-sen University – The Third Affiliated Hospital, Guangzhou, China, ⁶China-Japan Friendship Hospital, Beijing, China, ⁷The First Affiliated Hospital of Harbin Medical University, Harbin, China, ⁸West China Hospital, Sichuan University, Chengdu, China, ⁹UCB Pharma, Monheim, Germany, ¹⁰UCB Pharma, Tokyo, Japan, ¹¹UCB Pharma, Slough, United Kingdom, ¹²Peking University People's Hospital, Beijing, China
Background/Purpose: There are unmet needs for patients (pts) suffering from rheumatoid arthritis (RA) in China, where a limited number of anti-TNFs are available.1, 2 Certolizumab…
Abstract Number: 1280 • 2017 ACR/ARHP Annual Meeting
Clinical Outcomes of Juvenile Dermatomyositis Patients Treated with TNF-Inhibitors: A Retrospective Chart Review Katelyn Banschbach1, Ellen Go1 and Stacey Tarvin2, 1Indiana University School of Medicine, 2riley Hospital for Children, Indiana University
Katelyn Banschbach¹, Ellen Go² and Stacey Tarvin³, ¹Indiana University School of Medicine, Indianapolis, IN, ²Pediatrics, Indiana University School of Medicine, Indianapolis, IN, ³Riley Hospital for Children, Indiana University, Indianapolis, IN
Background/Purpose: To analyze the clinical outcomes of TNF-inhibitors as a steroid-sparing agent in the treatment of juvenile dermatomyositis (JDM). Methods: We performed a retrospective chart…
Abstract Number: 2459 • 2017 ACR/ARHP Annual Meeting
Incidence of Disease Worsening in Inflammatory Arthritis Patients on Long-Term Infliximab (Remicade®) Therapy
A Marilise Marrache¹, Allen J Lehman¹, Brendan Osborne¹, Eliofotisti Psaradellis², Julie Vaillancourt², Emmanouil Rampakakis² and Francois Nantel¹, ¹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ²JSS Medical Research, Montreal, QC, Canada
Background/Purpose: A recent randomized controlled study in a single country reported rates of disease worsening over a one-year follow-up period for innovator infliximab (IFX) and…
Abstract Number: 1310 • 2017 ACR/ARHP Annual Meeting
Maternal and Fetal Outcomes in a Cohort of Patients Exposed to Tumor Necrosis Factor Inhibitors throughout Pregnancy
Geneviève Genest¹, Karen Spitzer² and Carl Laskin³, ¹Allergy-Immunology, McGill University and McGill University Health Center, Montreal, QC, Canada, ²Trio Fertility, Toronto, ON, Canada, ³Medicine, Rheumatology and Obstetrics and Gynecology, University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada
Background/Purpose: Tumor Necrosis Factor inhibitors (TNFi) are increasingly used during pregnancy but are frequently withheld in the second or third trimester to minimize transplacental transfer…

« Previous Page
1
…
4
5
6
7
8
…
29
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.